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ABSTRACT
The epithelium of the airway has considerable capacity
to undergo repair. These repair processes are respon-
sible for maintaining and restoring function after injury
of the airways, which likely occurs often as a result of
infectious, toxic or other exposures. However, repair
processes need not be fully effective. Inadequate repair
can take a number of forms and may result in meta-
plasia, hyperplasia or fibrotic scarring. It is likely that
repair processes that lead to tissue disruption play an
important role in the chronic airways diseases, such as
asthma and bronchitis. Through delineation of these
processes, it may become feasible to target therapeutic
interventions in order to achieve more effective mainte-
nance of tissue structure.
Key words: fibrosis, hyperplasia, metaplasia, trans-
forming growth foetor-B.
INTRODUCTION
The airway epithelium possessesconsiderable capacity to
repair following injury. This repair involves an orderly
sequence of events. As demonstrated by Keenan et al.1
and by l.cne.? within 12 h of mechanical abrasion of the
trachea the denuded airway epithelial surface is recov-
ered by epithelial cells. These cells are markedly different
from normal epithelial cells; rather than being columnar
or cuboidal, they are exceedingly flattened. Following this
initial re-epithelialization, cellular proliferation begins. In
contrast with the relatively low rate of cellular prolifer-
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ation in the normal epithelium, where 5% or less of cells
may be dividinq.:' nearly every cell in an epithelial wound
may be dividing at 24 h. 1,2 As a result, cells accumulate
and differentiation begins. The cells acquire a columnar
phenotype over 3 days and eventually acquire features of
the differentiated pseudostratified columnar epithelium,
including secretory granules and cilia.
The initial cells present in the wound possess basal cell
mcrkers." These markers are expressed by cells that pro-
liferate and by columnar cells present at early stages in
the differentiation process. However, over 2 weeks cyto-
keratin 14, which is a marker of basal cells, becomes
restricted to cells that line the basement membrane. In
contrast, the columnar cells that are present by day
3 gradually assume positive staining for cytokeratin 18, a
marker of mature columnar cells, while losing positivity
for cytokeratin 14. This progression suggests that basal
cells are recruited into a wound where they de-differen-
tiate to cover the wound defect, proliferate and then
subsequently differentiate into both basal cells and
normal columnar epithelial cells. However, the alter-
native possibility that columnar cells on the edge of the
wound de-differentiate, acquire basal cell markers and
migrate to participate in wound repair is also consistent
with available data.
That airway epithelial cells have the capacity to migrate
into a wound is consistent with in vitro observations on the
chemotactic migration of these cells. Airway epithelial
cells, for example, are capable of migration towards a
number of stimuli, including insulin.? fibronectin? and
fragments of extracellular matix (EeM).7 Fibronectin is a
product of airway epithelial cells6.8 and this creates the
possibility that airway epithelial cells can produce a
chemotactic factor for neighboring epithelial cells. The
ability of airway epithelial cells to produce fibronectin can
be modulated by transforming growth factor (TGF)-~,
92 51 RENNARD
which can increase fibronectin production by epithelial
cells by five- to 1O-fold. 8,9 Because airway epithelial cells
can both produce TGF_~lO-12 and, at least in vitro,
release it in its active form.'? this creates the possibility
that airway epithelial cells can release TGF-~ that can
function in an autocrine or paracrine manner to stimulate
epithelial cell fibronectin production which, in turn, can
lead to the chemotactic recruitment of neighboring
epithelial cells into a wound (Fig. 1).
The migration of airway epithelial cells is a complex
process that takes place on an ECM surface. That is,
airway epithelial cells must be attached to a surface over
which they must craw!'? Therefore, migration of the cells
involves the ability of the leading edge of the cells to
advance, spread and attach to ECM components while
the trailing edge must de-attach. The nature of the
surface can affect cell migration. Specifically, epithelial
cells migrate more rapidly over interstitial ECM com-
ponents than they do over basement membrane
components." While the processes by which epithelial
cells attach to ECM are both complex and incompletely
understood, it is likely that cell surface integrins playa
prominent role. 13-1S Consistent with this, migrating
epithelial cells differentially express integrins during and
following wound repoir." It is also of interest that TGF-~
can dramatically affect cell surface integrin expression,
increasing the expression of these adhesive receptors.'?
Moreover, TGF-~-exposed airway epithelial cells are
markedly more adhesive than are control cells. 18
Interestingly, TGF-~-exposed cells are also significantly
less responsive to chemotactic stirnuli.!" This suggests
the very interesting possibility that TGF-~ released
centrally in a wound could function as an autocrine or
paracrine factor to cause the adhesive spreading of cells
within the wound, preventing them from exposing more
epithelium while at the same time driving these cells to
produce fibronectin, thus mediating the recruitment of
additional cells to help repair a defect (Fig. 1).
The ability of epithelial cells to respond in the repair
process can be modulated by other cytokines present in
the inflammatory milieu. In this respect, interleukin (IL)-4,
a characteristic Th2-derived cytokine, can inhibit TGF-
~-induced production of fibronectln.'? In contrast,
cytokines derived from cultured mononuclear phago-
cytes render airway epithelial cells more responsive to
chemotactic stimuli.i? Thus, the nature of the repair
response in the airway epithelium likely will depend not
only on the airway epithelial cells, but also on the pres-
ence and state of activation of other inflammatory cells.
Once recruited to sites of injury, airway epithelial cells
must proliferate. In this regard, epithelial cells will prolif-
erate in response to a number of growth factors21,22 and
Fig. 1 Model of epithelial repair following injury. Following loss of epithelial cells, basal cells remaining within the wound produce
active transforming growth factor (TGF)-~ (a). This TGF-~ functions to increase the adhesivity of nearby cells within the wound, induc-
ing them to spread and cover the wounded area. Transforming growth [octor-B also induces the production of increased amounts of
fibronectin (b). This fibronectin, in turn, can recruit cells from the edge of the wound that can also assist in repair of the defect (c).
Following this recruitment process, cells can proliferate and differentiate (see text for details).
their proliferation can be driven by supernatant medium
from cultured mononuclear phcqocvtes" or from fibre-
blcsts." This suggests that, as with chemotaxis, the
proliferative response of airway epithelial cells is likely to
be regulated by a number of components within an
inflammatory/reparative milieu. Proliferation of airway
epithelial cells is also regulated by the ECM.21,22,25 In this
regard, the composition of the ECM may be an important
determinant of both the rate of epithelial cell proliferation
and the responsiveness of epithelial cells to growth
factors. 26 Following accumulation, airway epithelial cells
must differentiate. This process likely involves the selec-
tive loss of cells through apoptosis, a process that can be
modulated by epithelial cell-matrix lntercctions." The
precise mechanisms that govern airway epithelial cell
differentiation remain to be determined, but it is likely that
interactions with ECM,27 the presence of cvtokines'" and,
possibly, the presence of the air interface on the airway
surfcce"? all contribute. If differentiation proceeds satis-
factorily, airway epithelial integrity can be restored. In
contrast, if re-epithelialization is incompletely effective,
hyperplastic and metaplastic lesions can develop.
In addition to airway epithelial cells, the mesenchymal
cells within the airway wall can participate in the repair
response. Overexuberant recruitment, proliferation and
activation of these cells can result in the accumulation
of peribronchiolar connective tissue. Like scar tissue any-
where, these tissues can contract and can result in airway
narrowing. This peribronchiolar fibrosis is thought to be a
major anatomic correlate of airflow limitation in individuals
with moderately severe chronic obstructive airway disease
(COPD).30-34 Similar lesions may account for fixed airflow
limitation in patients with chronic asthma.35,36
Taken together, these processes suggest a number of
potential opportunities to intervene in order to achieve a
more favorable outcome in airway disease. Specifically, it
may be possible to augment the normal reparative
process leading to restoration of epithelial integrity.
Alternatively, it may be possible to inhibit the develop-
ment of peribronchiolar fibrosis. With respect to this latter
possibility, peribronchiolar fibrosis could be blocked
either by inhibiting the release of mediators that drive the
fibrotic response or by directly inhibiting fibroblast
responses. In vitro evidence suggests that several agents
commonly used to treat airway disease may be active in
such pathways.
Many cells can release mediators that can drive
fibrotic responses, including lymphocytes,37,38 mono-
nuclear phagocytes,39,4o mast cells,41,42 fibroblasts and
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epithelial cells.43-46 In addition, profibrotic mediators can
be generated by activation of mediators present in the
extracellular milieu."? Among the cells that have the
capability of participating in driving a fibrotic response
are the epithelial cells, which appear to play an impor-
tant role in normal repair as well. Airway epithelial cells
can release mediators that can drive many aspects of the
fibrotic response, including fibroblast recruitment."
proliferation,44,48 matrix production:" and matrix re-
modelinq'" (Fig. 2).
Fibronectin released by airway epithelial cells can
recruit fibroblcsts'" as well as other epithelial cells." It is
possible that this pathway could be susceptible to thera-
peutic manipulation. Specifically, agents that increase
fibroblast cAMp, including prostaglandin E (PGE) and
~-adrenergic agonists, appear to block the chemotactic
response of fibroblasts towards fibronectin."? Inhibiting
fibroblast recruitment may have a number of advantages
as this recruitment process may select for fibroblasts with
specific synthetic capabilities. In in vitro systems, fibro-
blasts that migrate towards fibronectin are enriched for
a-smooth muscle actin 50 and, thus, have properties of
myofibroblasts.
Epithelial cells also have the capability of releasing
activities that can drive fibroblast proliferotion.v':" These
activities appear to be heterogeneous and several growth
factors are likely to be involved. The ability of fibroblasts
to respond to these growth factors can be blocked directly
by PGE.44 The release of these factors can be attenuated
by qlucocorticoids.?'
Airway epithelial cells can also drive fibroblast matrix
production, at least in part, by releasing TGF_~.46 The pro-
duction of matrix components can also be inhibited.
Again, agents that increase fibroblast cAMP levels have an
anti-fibrotic effect, inhibiting the production of type I colla-
gen.52 Glucocorticoids also have a modest effect in
inhibiting type I collagen produced by fibroblasts under
basal conditions,53-55 although they appear to have little
effect on fibronectin production (SI Rennard, unpubl. obs.,
1994). In contrast to their modest effect on basal rates of
fibroblast type I collagen production, glucocorticoids can
completely inhibit the TGF-~-driven augmentation of
fibroblast type I collagen production (SI Rennard, unpubl.
obs., 1994). Interestingly, glucocorticoids appear to have
no effect on epithelial cell-driven fibroblast fibronectin
production (DJ Romberger, unpubl. obs., 1994). This
raises the possibility that glucocorticoids may change the
relative composition of ECM by changing the ratio of
matrix components.
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Fig. 2 Epithelian cell-derived factors and peribronchiolar fibrosis. Mediators released by epithelial cells are capable of driving all
aspects of the fibrotic process, including fibroblast recruitment, proliferation and matrix production and remodeling. Interestingly,
some of the same mediators involved in epithelial repair, such as fibronectin and transforming growth factor (TGF)-~ can also lead
to mesenchymal cell recruitment and activation. The effects of potential therapeutic agents can be variable. Glucocorticoids, for
example, have no effect on fibroblast recruitment, can inhibit the release of growth factors from epithelial cells, can inhibit the
TGF-~-induced stimulation of collagen production by fibroblasts and can augment fibroblast induced matrix contraction (see text
for details).
Once ECM components are produced, they can
undergo extensive remodeling. This remodeling process,
which is believed to be mediated at least in part by the
ability of mesenchymal cells to contract the ECM, is a
process that can also be regulated by exogenous factors. 56
Transforming growth Ioctor-B derived from airway epithe-
lial cells, for example, can result in augmented contrac-
tion. 43 ~-Adrenergic agonists can inhibit this ccntroction"
Interestingly, glucocorticoids augment fibroblast mediated
contraction of ECM.58 Thus, ~-adrenergic agonists and
other agents that increase fibroblast cAMP appear to
inhibit all aspects of fibroblast responses that may be con-
sidered pro-fibrotic. Glucocorticoids, in contrast, do not
appear to affect chemotactic recruitment, while they can
inhibit proliferation. Glucocorticoids can inhibit the pro-
duction of type I collagen, but not of other matrix com-
ponents, such as fibronectin. Finally, glucocorticoids can
exert a pro-fibrotic response augmenting fibroblast-
mediated collagen gel contraction. This suggests that the
effects of some agents, such as glucocorticoids, on the
fibrotic response may differ for various parts of the fibrotic
response (Fig. 2). Perhaps it is such mixed effects that
account for the variable therapeutic utility of glucocorti-
coids in fibrotic conditions.
The assessment of any therapeutic intervention in
modulating peribronchiolar fibrosis in chronic obstructive
pulmonary diseases will be exceedingly difficult to demon-
strate clinically. This is due to the relatively slowly
progressive nature of these disorders and the relatively
imprecise measurements that can be made in order to
follow progression; that is, forced expiratory volume in
one second (FEV1) . It has been estimated that, in order to
demonstrate a therapeutic benefit of an intervention to
modify the natural history of COPD, over 1000 patients
would have to be followedfor at least 3 years at a cost of
greater than Canadian $20 million.t" For this reason, the
ability to assess intermediate end-points will have great
utility in designing clinical strategies. With regard to the
fibrotic response, this raises a number of potential points
of interest. Specifically, the production of mediators rele-
vant to the fibrotic response may be addressed in tissue
samples by either immunohistochemical or in situ hybridi-
zation methods. Similarly, the responsiveness of cells to
pro-fibrotic mediators could be assessed using either
markers of cellular proliferation or markers of matrix pro-
duction, such as immunohistochemistry for procollagen
peptides. Assessment of soluble markers of matrix bio-
synthesiswould also be a reasonable possibility.
The ability to manipulate the cellular and biochemical
responses that underlie both normal and abnormal repair
in the airway are beyond current clinical capabilities.
Nevertheless, these represent important avenues for
future investigations. Current understanding of these
processes can permit the in vitro assessment of potential
therapeutic interventions. Recent advances along these
lines raise the possibility that such potential interventions
could be tested, at least with respect to proof concept, in
human disease in vivo. Ultimately, however, it will be nec-
essary for such interventions to be tested in rigorous
clinical trials. Considering that no effective therapies are
currently available that can alter the relentlessly progres-
sive natural history of COPO, the development of such
therapeutic interventions should remain a high priority.
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